Use of Direct Oral Anticoagulants in Patients with Sickle Cell Disease and Venous Thromboembolism: A Prospective Cohort Study of 12 Patients
| Autor: | Julien Bertolino, Jean-Robert Harlé, Mikael Ebbo, Emmanuelle Bernit, E. Jean, Gabrielle Sarlon, Laurence Camoin, Jacques-Robert Christen, Nicolas Schleinitz |
|---|---|
| Přispěvatelé: | Hôpital d'Instruction des Armées Laveran, Service de Santé des Armées, Aix-Marseille Université - Faculté de médecine (AMU MED), Aix Marseille Université (AMU), Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Assistance Publique - Hôpitaux de Marseille (APHM), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Médecine Interne [Hôpital Saint-Joseph - Marseille], Aix Marseille Université (AMU)-Hôpital Saint-Joseph [Marseille], Service de Chirurgie, Assistance Publique - Hôpitaux de Marseille (APHM)-Hospices Civiles de Marseille-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Hôpital de la Timone [CHU - APHM] (TIMONE), Département de Médecine Interne (DMI - MARSEILLE), Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU), Assistance Publique-Hôpitaux de Marseille (AP-HM) |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty Pyridones Clinical Biochemistry Hemorrhage Disease Anemia Sickle Cell 030204 cardiovascular system & hematology Cohort Studies 03 medical and health sciences Young Adult 0302 clinical medicine Rivaroxaban [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases Internal medicine Medicine Humans In patient [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology cardiovascular diseases Prospective Studies Prospective cohort study Genetics (clinical) ComputingMilieux_MISCELLANEOUS [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases business.industry Biochemistry (medical) Hematology Venous Thromboembolism Middle Aged equipment and supplies [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology 3. Good health Increased risk Treatment Outcome Young population [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology Pyrazoles Apixaban Female business Venous thromboembolism 030215 immunology medicine.drug Factor Xa Inhibitors |
| Zdroj: | Hemoglobin Hemoglobin, 2019, 43 (4-5), pp.296-299. ⟨10.1080/03630269.2019.1689997⟩ Hemoglobin, Informa Healthcare, 2019, 43 (4-5), pp.296-299. ⟨10.1080/03630269.2019.1689997⟩ |
| ISSN: | 0363-0269 1532-432X |
| Popis: | Patients with sickle cell disease have an increased risk of venous thromboembolism (VTE) and with a mortality 2-fold higher. The anticoagulation of VTE in a young population is an important question. Indeed, hemorrhagic complications of anticoagulation may occur more frequently than in the general population. The use of a direct oral anticoagulant (DOAC) is not recommended for VTE in patients with sickle cell disease because those patients were not included in the clinical studies. We aimed to study the safety of using DOACs in a prospective cohort of patients with sickle cell disease and VTE. We prospectively followed the cohort of all sickle cell disease patients undergoing recent DOAC treatment for VTE at a sickle cell disease reference center. Twelve patients received rivaroxaban for VTE (eight women and four men). The median age was 27 years (20-45). The sickle cell disease variants included homozygous Hb SS ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|